Related Experiment Videos
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength
1Metabolic Disorders Research, M/S 15-2-B, Amgen Inc, 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA. paulk@amgen.com
Current Opinion in Pharmacology
|September 29, 2005
Summary
Osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand (RANKL) regulate bone resorption. Denosumab, an OPG-like antibody, inhibits RANKL, offering a potential therapeutic for bone diseases.
Area of Science:
- Bone biology and metabolism
- Endocrinology and skeletal diseases
Background:
- Osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand (RANKL) are key regulators of bone resorption.
- Hormones, cytokines, and growth factors influence bone resorption by modifying the RANKL/OPG ratio.
- Altered RANKL and OPG expression is implicated in various bone diseases.
Purpose of the Study:
- To investigate the roles of OPG and RANKL in bone resorption.
- To evaluate Denosumab (AMG 162) as a therapeutic agent targeting RANKL.
Main Methods:
- Review of literature on OPG and RANKL in bone metabolism.
- Characterization of Denosumab as a monoclonal antibody to RANKL.
Main Results:
- RANKL promotes osteoclast formation, function, and survival.
- OPG inhibits RANKL activity, suppressing bone resorption and enhancing bone density and strength.
- Denosumab mimics OPG's effects with an extended half-life for less frequent administration.
Conclusions:
- OPG and RANKL are critical in regulating bone resorption and are implicated in bone diseases.
- Denosumab represents a promising therapeutic strategy for bone conditions by inhibiting RANKL.